


Top 20 Biologics

A biopharmaceutical R&D pipeline list



Top 20 Biologics 2006

www.lamerie.com

February 2007

La:Merie
Business intelligence

Index

Top 20 Biologics 2006

1. Abstract	3
2. Competitor Analysis	
• Top 20 Blockbusters	3
• Top Selling Classes of Biological Products	5
• Growth Rates (2006 vs 2005)	6
• EPOs	7
• Cancer Antibodies	8
• Anti-TNF Biologics	9
• Insulin Aroducts	10
• Rec. Coagulation Factors	11
• Interferon beta	12
• G-CSF	13
• human Growth Hormone	14
• Interferon alfa	15
• Enzyme Replacement	16
• Antiviral Antibody	17
• Follicle Stimulating Hormones	17
• Selected Other Biologics	18
3. About La Merie Business Intelligence	19

Abstract

Top 20 Biologics 2006

TOP Classes of Biologics with 2006 Sales of US\$ 63.8 bln

The major cancer antibodies Rituxan, Herceptin, Avastin and Erbitux represent the no. 2 class of top selling biologics with the highest growth rate of 57 % and combined 2006 sales of US\$ 10.6 bln. In contrast, the class of erythropoietin products still had the highest sales in 2006 with US\$ 11.9 bln, but with the lowest growth rate (6.7 %) of all 12 classes of recombinant biologics (excluding vaccines) with sales higher than US\$ 1 bln. The single biologic product with highest sales in 2006 was the anti-TNF drug Enbrel (US\$ 4.5 bln), but Humira had the highest growth rate (+ 46 %) among the anti-TNF antibodies which are the no. 3 class with combined 2006 sales of US\$ 10.3 bln. The increasing conversion of insulin to insulin analogs explains the growth rate of 24 % in the class of insulin products with sales of US\$ 9 bln in 2006. Recent new product launches contributed to the 28 % growth of enzyme replacement therapies to 2006 sales of US\$ 1.7 bln. Recombinant coagulation factors posted 2006 sales of US\$ 4.7 bln (+ 17 %). Total sales of the 12 top selling biologic products with sales per class over US\$ 1 bln grew by 20 % from US\$ 53 bln to US\$ 63.8 bln in 2006.

By La Merie Business Intelligence

Top 20 Biologics

ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	2006 sales (mln)
1	Enbrel / Embreli; etanercept	TNF-alpha	Fusion protein of Fc + sol TNF-R	Amgen & Wyeth & Takeda	Antibody	Rheumatoid arthritis; psoriasis etc	US\$ 4,474
2	Aranesp	EPO-R	Rhu darbepoetin alfa	Amgen	Protein	Renal and cancer anemia	US\$ 4,121
3	Rituxan / MabThera; rituximab	CD20	Rec chimeric mab	Genentech/ Roche /Chugai Biogen IDEC, Zenyaku Kogyu	Antibody	1 st line treatment of diffuse, large B-cell, CD20+ NHL plus chemotherapy	US\$ 3,912
4	Remicade; infliximab	TNF-alpha	Rec chimeric mab	Centocor (J&J) & Schering-Plough & Tanabe Seiyaku	Antibody	Rheumatoid arthritis etc	US\$ 3,764
5	Procrit / Eprex	EPO-R	Rhu epoetin alfa	Johnson & Johnson	Protein	Renal and cancer anemia	US\$ 3,180
6	Herceptin, trastuzumab	HER2	Rec humanized mab	Roche / Genentech	Antibody	Metastatic breast cancer	US\$ 3,175
7	Epogen / ESPO	EPO-R	Rhu epoetin alfa	Amgen & Kirin	Protein	Renal and cancer anemia	US\$ 2,844
8	Neulasta; peg- filgrastim	CSF-receptor	Pegylated G-CSF	Amgen	Protein	Neutropenia	US\$ 2,710
9	Actrapid / Novolin; Insulatard; Mixtard	Insulin receptor	Rhu insulin and related products	NovoNordisk	Protein	Diabetes	US\$ 2,653
10	Avastin; bevacizumab	VEGF	Rec humanized mab	Roche & Genentech	Antibody	Metastatic colorectal cancer	US\$ 2,395

Top 20 Biologics


ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	2006 sales (mln)
11	Lantus; insulin glargine	Insulin receptor	Rhu insulin analog	Sanofi-Aventis	Protein	Diabetes mellitus	US\$ 2,188
12	Humira; adalimumab	TNF-alpha	Rec fully human mab	Abbott (& Eisai)	Antibody	Rheumatoid arthritis, psoriasis etc	US\$ 2,044
13	Levemir; NovoLog (Mix)	Insulin receptor	Rhu insulin analogues aspart and detemir	Novo Nordisk	Protein	Diabetes	US\$ 1,908
14	Neo-recormon / Epogin	EPO-R	Rhu epoetin beta	Roche & Chugai	Protein	Renal and cancer anemia	US\$ 1,794
15	Avonex; interferon beta-1a	IFN-R	Rhu interferon β -1a	Biogen Idec	Protein	Multiple sclerosis	US\$ 1,707
16	Rebif; interferon beta-1a	IFN-R	Rhu interferon β -1a	Merck Serono	Protein	Multiple sclerosis	Full year estimate of US\$ 1,418
17	Neupogen / GRAN; filgrastim	G-CSF-receptor	rhu G-CSF	Amgen & Kirin	Protein	Neutropenia	US\$ 1,344
18	Humalog; insulin lispro	Insulin receptor	Rhu insulin analog	Eli Lilly	Protein	Diabetes	US\$ 1,300
19	Betaferon / interferon beta-1b	IFN-R	Rhu interferon β -1b	Bayer Schering Pharma	Protein	Multiple sclerosis	Full year estimate of US\$ 1,273
20	Pegasys; peginterferon alfa-2a	IFN-R	Pegylated recombinant interferon	Roche	Protein	Hepatitis B and C	US\$ 1,186

Top 20 Biologics

No.	Class of Products	2006 sales (US\$ bln.)	Selected Branded Products
1	Erythropoietins	11.94	Aranesp, Procrit Eprex, Epogen, Neo-Recormon, ESPO
2	Major cancer antibodies	10.62	Rituxan/MabThera, Herceptin, Avastin, Erbitux, Vectibix
3	Anti-TNF antibodies	10.28	Enbrel, Remicade, Humira
4	Insulin and insulin analogs	8.97	Humalog, Humulin, Lantus, Levemir, Novorapid, Actrapid, Novolin
5	Rec. coagulation factors	4.71	Novoseven, Kogenate, Helixate, Refacto, Advate, Recombinate, Benefix
6	Interferon beta	4.40	Avonex, Rebif, Betaferon / Betaseron
7	G-CSF	4.36	Neulasta, Neupogen, Neutrogen, GRAN
8	Human growth hormone	2.47	Genotropin, Norditropin, Humatrope, Nutropin, Saizen, Serostim
9	Interferon alpha	2.26	Pegasys, Peg-Intron, Intron A
10	Enzyme Replacement	1.71	Cerezyme, Fabrazyme, Aldurazyme, Myozyme, Replagal, Naglazyme, Elaprase
11	Antiviral antibody	1.1	Synagis
12	Follicel stimulating hormones	1.04	Gonal-f, Puregon
	Total:	63.83	

Top 20 Biologics

Growth Rates (2006 vs 2005) of Top-Selling Classes of Biological Products



Top 20 Biologics

Product Type: Pharmaceutical		Category: EPOs – No. 1						
ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year (%)
134	Aranesp	EPO-R	Rhu darbepoetin alfa	Amgen	Protein	Renal and cancer anemia		US\$ 4,121 (+ 26 %) source
509	KRN321	EPO-R	Rhu darbepoetin alfa	Kirin (from Amgen)	Protein	Anemia	2007	2007 sales expectations of Yen 2.4 bln source
330	Procrit / Eprex	EPO-R	Rhu epoetin alfa	Johnson & Johnson (from Amgen)	Protein	Renal and cancer anemia		US\$ 3,180 (- 4 %) source
505	Epogen	EPO-R	Rhu epoetin alfa	Amgen	Protein	Renal and cancer anemia		US\$ 2,511 (+ 2 %) source
506	ESPO	EPO-R	Rhu epoetin alfa	Kirin (from Amgen)	Protein	Anemia		Yen 40.0 bln (- 3.1 %) = US\$ 333 source
507	Neo-recormon	EPO-R	Rhu epoetin beta	Roche	Protein	Renal and cancer anemia		NeoRecormon: CHF 1,500 (+ 6 %) = US\$ 1,210 source Copbined epoetin beta sales: CHF 2,227 (- 1 %) = US\$ 1,794 source
508	Epogin	EPO-R	Rhu epoetin beta	Chugai (Roche)	Protein	Renal and cancer anemia		YEN 63.4 bln (- 8.4 %)) US\$ 524 mln source
								Total: US\$ 11.939 bln

Related Competitor Analysis: [EPO](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: Cancer antibodies - No. 2						
ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year (%)
344	Rituxan / MabThera; rituximab	CD20	Rec chimeric mab	Genentech/ Roche /Chugai Biogen IDEC, Zenyaku Kogyu	Antibody	1 st line treatment of diffuse, large B-cell, CD20+ NHL plus chemotherapy	1997	CHF 4,839 (+ 15 %) = US\$ 3,912 source
450	Herceptin, trastuzumab	HER2	Rec humanized mab	Roche / Genentech	Antibody	Metastatic breast cancer		CHF 3,927 (+ 81 %) = US\$ 3,175 source
460	Avastin; bevacizumab	VEGF	Rec humanized mab	Roche / Genentech	Antibody	Metastatic colorectal cancer		CHF 2,962 (+ 76) = US\$ 2,395 source
387	Erbbitux; cetuximab	EGF-R	Rec chimeric mab	Bristol-Myers Squibb (from ImClone)	Antibody	Refractory metastatic colorectal cancer		US: US\$ 652 (+ 58 %) source (total Erbbitux sales: US\$ 1094.6)
387	Erbbitux; cetuximab	EGF-R	Rec chimeric mab	Merck KGaA (from ImClone)	Antibody	Refractory metastatic colorectal cancer		Non-US: € 337 mln (+ 55 %) = US\$ 442.6 source
273	Vectibix; panitumumab	EGF-R	Rec fully human mab	Amgen	Antibody	3rd line metastatic colorectal cancer	2006	US\$ 39 source
								Total: 10.617 bln

Related Competitor Analysis: [VEGF and VEGF-R Agonists, Antagonists and Inhibitors](#)
[CD20 Antibodies](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: Anti-TNF Biologics – No. 3						
ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year (%)
746	Enbrel; etanercept	TNF-alpha	Fusion protein of Fc + sol TNF-R	Amgen	Fusion protein	Rheumatoid arthritis; psoriasis etc		US: US\$ 2,879 (+ 12 %) source
746	Enbrel; etanercept	TNF-alpha	Fusion protein of Fc + sol TNF-R	Wyeth (from Amgen)	Fusion protein	Rheumatoid arthritis; psoriasis etc		Ex-US and Canada: US\$ 1,499.6 (+ 38 %) source
746	Embrel; etanercept	TNF-alpha	Fusion protein of Fc + sol TNF-R	Takeda Pharmaceuticals (from Wyeth)	Fusion protein	Rheumatoid arthritis; psoriasis etc	2005	Full fiscal year 2006 estimate of Y 11.5 bln (+ 146 %) = US\$ 95.5 mln based on Q1-3 results source Co-promotion with Wyeth KK
458	Remicade; infliximab	TNF-alpha	Rec chimeric mab	Centocor / J&J	Antibody	Rheumatoid arthritis etc (10 indications)		Exclusive US\$ = 2,355 (+ 14 %) source and Intl (658: + 40 %)
458	Remicade; infliximab	TNF-alpha	Rec chimeric mab	Tanabe Seiyaku (from Centocor)	Antibody	Rheumatoid arthritis; psoriasis etc		Forecast fiscal year 2006: Yen 20.3 bln (+ 75.2 %) = US\$ 169 source for Japan and certain Asian countries
458	Remicade; infliximab	TNF-alpha	Rec chimeric mab	Schering-Plough	Antibody	Rheumatoid arthritis; psoriasis etc		US\$ 1,240 (+ 32 %*) source For non-US territory = RoW except US, Japan and certain Asian countries (Tanabe territories)
332	Humira adalimumab	TNF-alpha	Rec fully human mab	Abbott (& Eisai)	Antibody	Rheumatoid arthritis; psoriasis etc		US\$ 2,044 (+ 45.9 %) source In Japan not yet approved, but NDA for RA submitted in 2005
								Total: 10.282 bln

Related Competitor Analysis: [TNF Antagonists](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: Insulin products – No. 4						
ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year (%)
1307	Humalog; insulin lispro	Insulin receptor	Rhu insulin analog	Eli Lilly	Protein	Diabetes		US\$ 1,300 (+ 9 %) source
1841	Humulin	Insulin receptor	Rhu insulin	Eli Lilly	Protein	Diabetes		US\$ 925 (- 8 %) source
1842	Lantus; insulin glargine	Insulin receptor	Rhu insulin analog	Sanofi-Aventis	Protein	Diabetes mellitus		€ 1.666 (+ 36.9 %) = US\$ 2,188 read more
658	Levemir	Insulin receptor	Rhu (basal) insulin analogue detemir	Novo Nordisk	Protein	Diabetes		Combined sales of Novo's insulin analogs: DKK 10,825 (+ 48 %) = US\$ 1,908 source
457	NovoLog (Mix)	Insulin receptor	Rhu rapid acting insulin analogue aspart	Novo Nordisk	Protein	Diabetes		
1843	Actrapid / Novolin; Insulatard; Mixtard	Insulin receptor	Rhu insulin and related products	Novo Nordisk	Protein	Diabetes		DKK 15,057 (+/- 0 %) = US\$ 2,653 source
								Total: US\$ 8.974 bln

Related Competitor Analysis: [Insulin](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: Rec. coagulation factors – No 5					
Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st appr oval	2006 sales (mln) vs. previous year
376	NovoSeven; eptacog alfa	Coagulation factor replacement	Novo Nordisk	Protein	Hemophilia		DKK 5,635 (+ 11 %) = US\$ 993 source
377	Kogenate FS + BioSet; octocog	Coagulation factor replacement	Bayer Schering Pharma	Protein	Hemophilia A		Full year estimate based on 9-mth sales: € 776 (+ 19.8 %) = US\$ 1019 source
988	Helixate FS	Factor VIII substitution	CSL Behring (from Bayer Schering)	Cardio-vascular & blood	Hemophilia A		US\$ 340 mln source
329	Advate; rAHF	Factor VIII substitution	Baxter	Cardio-vascular & blood	Hemophilia A		With BaxJECT II device; same source as Recombinate 2006 sales estimate of US\$ 806 mln (from 9-mths sales source)
987	Recombinate rAHF	Factor VIII substitution	Baxter (from GI/Wyeth)	Cardio-vascular & blood	Hemophilia A		Combined 2006 sales of Recombinate and Advate = US\$ 1,523 mln (+ 11.4 %) source
375	Refacto	Coagulation factor replacement	Wyeth	Protein	Hemophilia A		US\$ 305.6 (+ 13.9 %) source
426	Benefix; Nonacog alfa reformulated	Coagulation factor replacement	Wyeth	Protein	Hemophilia B		US\$ 357.6 (+ 4.2 %) source
426	BeneFIX; Nonacog alfa reformulated	Substitution of factor IX	Baxter (exclusive in Europe)	Cardio-vascular & blood	Hemophilia B		2006 sales of US\$ 173 mln (difference of all recombinants source and F. VIII products source)
							Total: US\$ 4.711 bln

Related Competitor Analysis: [Coagulation Factors](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: Interferon beta – No- 6						
	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2005 sales (mln) vs. previous year (%)
1123	Avonex; interferon beta-1a	IFN-R	Rhu interferon β -1a	Biogen Idec	Protein	Multiple sclerosis		US\$ 1,707 (+ 8.9 %) source
1002	Rebif; interferon beta-1a	IFN-R	Rhu interferon β -1a	Merck Serono	Protein	Multiple sclerosis		Full year estimate of US\$ 1,418 (+ 13.8 %) based on 9-mths results source
496	Betaferon / Betaseron; interferon beta-1b	IFN-R	Rhu interferon β -1b	Bayer Schering Pharma	Protein	Multiple sclerosis		Full year estimate of € 969 (+ 16 %) = US\$ 1,273 based on 9-mths results source
								Total: US\$ 4.398 bln

Related Competitor Analysis: [Interferon](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: G-CSF – No. 7						
ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year (%)
459	Neulasta; peg-filgrastim	CSF-receptor	Pegylated G-CSF	Amgen	Protein	Neutropenia		US\$ 2,710 (+ 18.4 %) source
618	Neupogen; filgrastim	CSF-receptor	rhu G-CSF	Amgen	Protein	Neutropenia		US\$ 1,213 (+/- 0 %) source
618	GRAN; filgrastim	CSF-receptor	rhu G-CSF	Kirin (from Amgen)	Protein	Neutropenia		Yen 15.7 bln (- 0.4 %) = US\$ 130.7 source
1844	Neutrogen; lenograstim	CSF-receptor	Rhu G-CSF	Chugai (Roche)	Protein	Neutropenia associated with chemotherapy		CHF 379 (+ 9 %) = US\$ 305.8 source
								Total: > US\$ 4.360 bln

Related Competitor Analysis: [G-CSF](#) and [GM-CSF](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: human Growth Hormone – No. 8						
ID No.	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year (%)
1244	Genotropin	Regulation of postnatal growth	Rec human growth hormone	Pfizer	Protein	Growth hormone deficiency		US\$ 795 (- 5 %) PR 01-22-07
1246	Norditropin	Regulation of postnatal growth	Rec human growth hormone	Novo Nordisk	Protein	Growth hormone deficiency		DKK 3,309 (+ 19 %) = US\$ 583 source
1245	Humatrope;	Regulation of postnatal growth	Ec human growth hormone	Eli Lilly	Protein	Growth hormone deficiency		Estimate of US\$ 397 (- 4%)
1243	Nutropin; Protropin; somatropin; somatrem	Regulation of postnatal growth	Rec human growth hormone	Genentech (Roche)	Protein	Growth hormone deficiency		CHF 494 (+ 3) = US\$ 399 source
1243	Nutropin AQ Pen; somatropin	Regulation of postnatal growth	Rec human growth hormone	Ipsen (from Genentech / Roche)	Protein	Growth hormone deficiency		€ 14.7 (+ 157 %) = US\$ 19.3 source License for RoW except North America and Japan
1247	Saizen / Serostim	Regulation of postnatal growth	Rec human growth hormone	Merck Serono	Protein	Growth hormone deficiency		Full year estimates based on 9-mths results Saizen: US\$ 205.6 (+ 1.3 %) Serostim: US\$ 70.1 (+ 1.4 %) Total: US\$ 275.7
								Total: US\$ 2.469 bln

Related Competitor Analysis: [Human Growth Hormone \(hGH\)](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: Interferon alfa – No. 9						
	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year (%)
721	Pegasys; peginterferon alfa-2a	IFN-R	Pegylated recombinant interferon	Roche	Protein	Hepatitis B and C		CHF 1,467 (+ 3 %) = US\$ 1,186 source
264	Peg-Intron; pegylated interferon alfa-2b	IFN-R	Pegylated interferon alfa-2b	Schering-Plough	Protein	Hepatitis C		US\$ 837 (+ 11 %) source
1022	Intron A; interferon alfa-2b	IFN-R	Rhu interferon alfa-2b	Schering-Plough	Protein	Hepatitis		US\$ 237 (- 17 %) source
								Total: US\$ 2.26 bln

Related Competitor Analysis: [Interferon](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: Enzyme Replacement – No. 10						
	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (US\$ mln) vs. previous year
1742	Cerezyme; imiglucerase	Beta-glucocerebrosidase replacement	Imiglucerase for injection	Genzyme	Protein	Gaucher's disease		1,007 (+ 8 %) source
204	Fabrazyme; agalsidase beta	Alpha galactosidase A replacement	Rhu enzyme	Genzyme	Protein	Fabry disease		359 (+ 18 %) source
263	Myozyme; alglucosidase alfa	Acid-alpha-glucosidase replacement	Rhu enzyme	Genzyme	Protein	Pompe disease		59 (new) source
074	Aldurazyme; laronidase	Alpha-L-iduronidase replacement	Rhu enzyme	Genzyme & BioMarin	Protein	Hurler and Hurler-Scheie forms of mucopolysaccharidosis I (MPS I)		96.3 (+ 26 %) source Total product sales of Joint Venture
068	Elaprase; idursulfase	Iduronate-2-sulfatase replacement	Rhu enzyme	Shire (from TKT)	Protein	Hunter syndrome (MPS II)		Launched in US in Q3/2006: 23.6 source positive opinion from EMEA, EU launche starting early 2007
1845	Replagal; agalsidase alfa	Alpha-galactosidase replacement	Rhu enzyme	Shire & Daiippon Sumitomo	Protein	Fabry disease		Marketed in Europe: 117.7 (+ 24 %) source Japanese launch by end of Q1/2007
122	Naglazyme; galsulfase	N-acetyl-galactosamine 4-sulfatase replacement	Rhu enzyme	BioMarin	Protein	MPS VI		46.5 (first full year) source
								Total: 1.709 bln

Related Competitor Analysis:

Top 20 Biologics

Product Type: Pharmaceutical							Category: Antiviral antibody – No. 11		
Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year		
091	Synagis, palivizumab	Rec humanized mab	MedImmune	Antibody	Prevention of RSV in pre-mature infants	1999	US\$ 1,065 (+ %) source US-sales of \$ 906 mln; sales to Abbott: \$ 159 source Now exclusive in US, US co-promotion with Abbott terminated in June 2006		
091	Synagis, palivizumab	Rec humanized mab	Abbott International (Ross Division for USA)	Antibody	Prevention of RSV in pre-mature infants		Half-year co-promotion sales in 2006 estimated to be around 50 % of 2005 sales of \$ 231 mln (= \$ 115 mln) source		

Related Competitor Analysis:

Product Type: Pharmaceutical							Category: Follicle stimulating hormones – No. 12		
Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year (%)		
868	Gonal-f; follitropin alfa	Rhu Follicle stimulating hormone	Merck Serono	Protein	Infertility		Full year estimate based on 9-mths data: US\$ 535 (- 3 %) source		
1278	Puregon; Follistim follitropin betra	Rhu Follicle stimulating hormone	Organon	Protein	Infertility		€ 384 (+ 8 %) = US\$ 504 source		
							Total: US\$ 1.039 mln		

Related Competitor Analysis: [Follicle Stimulating Hormone \(FSH\)](#)

Top 20 Biologics

Product Type: Pharmaceutical		Category: Selected Other Biologics						
	Product Name	Target / Mechanism of Action	Class of Compound	Company	Product Category	Indication	1st approval	2006 sales (mln) vs. previous year (%)
160	Forteo; teriparatide	PTH-R	Rhu peptide (PTH 1-34)	Eli Lilly	Peptide	Osteoporosis		US\$ 594.3 (+ 53 %) source
159	Preotact (EU) / Preos (US)	PTH-R	Rhu peptide (PTH 1-84)	NPS Pharmaceuticals & Nycomed	Peptide	Osteoporosis	2006	€ 0.7 mln (US\$ = 0.92 mln) source Start of EU launches in June 2006 (US NDA still under review)
282	Byetta; exenatide	GLP-1 receptor	GLP-1 analog	Eli Lilly & Amylin Pharmaceuticals	Peptide	Diabetes	2005	US\$ 430.2 source
1350	Raptiva; efalizumab	CD11a	Rec humanized mab	Genentech (Roche) & Merck Serono	Antibody	Mild to moderate psoriasis		US: US\$ 90 (+ 14 %) source Ex-US : full year estimate of US\$ 64.9 (+ 123 %) based on 9-mths data source total: US\$ 154.9
1846	Pulmozyme; dornase alfa	DNA	Rhu protein	Genentech (Roche)	Protein	Cystic fibrosis		US\$ 351 (+ 11 %) source
208	Lucentis; ranibizumab	VEGF	Rec humanized Fab	Genentech (Roche) & Novartis	Antibody	Wet age-related macular degeneration	2006	US: US\$ 380 (Q4: 218) source
013	Orencia; abatacept	CD80/CD86 (B7.1 + B7.2)	Rec fusion protein of CTLA4 + Fc	Bristol-Myers Squibb	Fusion protein	Rheumatoid arthritis	2005	US\$ 89 source
268	Xolair; omalizumab	IgE	Rec humanized mab	Genentech (Roche) & Novartis	Antibody	Asthma		US: US\$ 425 (+ 33 %) source Ex-US : US\$ 102 source Combined : US\$ 527
1153	rhBMP2; InductOs	Tissue regeneration	Rhu growth factor	Wyeth	Protein	Spinal fusion + long bone fusion		US\$ 307.9 (+ 30.3 %) source

Related Competitor Analysis: [GLP-1 Analogs](#)

[Psoriasis](#)

[Wet Age-Related Macular Degeneration \(AMD\)](#)

About

La Merie Business Intelligence



La Merie Business Intelligence provides R&D information to the pharmaceutical industry. Our deliverables are a tool for your innovation in R&D based on selected, relevant and validated information.

La Merie Business Intelligence was founded in 2002 by Dr. Ulrich Martin to provide expert consulting services to the pharmaceutical industry. Based on his extensive experience in the pharmaceutical industry both as a physician specializing in pharmacology and as a co-founder and CEO of a product development company, La Merie Business Intelligence provides R&D information by individual consultancy, standard Competitive Intelligence reports and by online content at PipelineReview.com.

The Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. Competitor analysis reports can be purchased online at PipelineReview.com as individual, single products or obtained by subscribing to R&D Pipeline News published weekly 50-times a year. Each issue of R&D Pipeline News contains at least two competitor evaluations.

PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry.

PipelineReview.com

By La Merie ●●● Business Intelligence Center